Posted by Michael Wonder on 27 Oct 2023
Catalyst Pharmaceuticals reports FDA approval of Agamree (vamorolone) for Duchenne muscular dystrophy granted to Santhera Pharmaceuticals
26 October 2023 - Catalyst expects to commercially launch Agamree in Q1, 2024.
Catalyst Pharmaceuticals today reported that Santhera Pharmaceuticals has obtained US FDA approval for Agamree (vamorolone) oral suspension 40 mg/mL for use in treating Duchenne muscular dystrophy in patients aged two years and older.
